Outcomes after daunorubicin dose randomization. (A) Overall survival (OS); (B) cumulative incidence of relapse; (C) OS—favorable cytogenetics; (D) OS—intermediate cytogenetics; (E) OS—adverse cytogenetics; (F) survival censored at transplant.